How many insider trades does FilingIQ track for RLMD?

FilingIQ tracks 233 Form 4 insider transactions for RLMD (RELMADA THERAPEUTICS, INC.), covering filings from Dec 14, 2015 onwards. 0 of those were filed in the last 90 days.

Are RLMD insiders net buyers or net sellers?

Across the full Form 4 history for RLMD, 88 transactions (38%) were open-market purchases and 86 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RLMD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RLMD in?

RELMADA THERAPEUTICS, INC. (RLMD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $319.73M.

RLMD insider trading

NasdaqCM Healthcare

RELMADA THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

233

Last 90 days

Buys / sells

38% / 37%

Market cap

$319.73M

About RELMADA THERAPEUTICS, INC.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Company website: www.relmada.com

RLMD insider activity at a glance

FilingIQ has scored 233 insider transactions for RLMD since Dec 14, 2015. The most recent filing in our index is dated Dec 15, 2025.

Across the full history, 88 open-market purchases and 86 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RLMD insider trades is 55.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RLMD trades on FilingIQ Raw filings on SEC EDGAR

Latest RLMD Form 4 filings

TRAVERSA SERGIO Chief Executive Officer

P Nov 5, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding RLMD

VR Adviser, LLC

$56.20M · 8.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for RLMD?: FilingIQ tracks 233 Form 4 insider transactions for RLMD (RELMADA THERAPEUTICS, INC.), covering filings from Dec 14, 2015 onwards. 0 of those were filed in the last 90 days.
Are RLMD insiders net buyers or net sellers?: Across the full Form 4 history for RLMD, 88 transactions (38%) were open-market purchases and 86 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RLMD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RLMD in?: RELMADA THERAPEUTICS, INC. (RLMD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $319.73M.

Methodology & sources

Every RLMD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.